Cargando…

Rapidly Progressive Cognitive Decline and Varicella Zoster Blisters Associated With Teprotumumab in 2 Patients With Graves’ Orbitopathy

Introduction: Teprotumumab, an IGF-1R antagonist, was approved for treatment of Graves’ orbitopathy (GO) in 2020. Common side effects include nausea, diarrhea, muscle spasms, hearing impairment, dysgeusia, headache, dry skin, infusion reactions, and hyperglycemia. We report here 2 cases of unexpecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoang, Thanh Duc, Chou, Eva, Nguyen, Nguyen T, Shakir, Mohamed K M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135408/ http://dx.doi.org/10.1210/jendso/bvab048.1941

Ejemplares similares

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

Role of teprotumumab in the treatment of active moderate-to-severe Graves’ orbitopathy
por: Bartalena, Luigi
Publicado: (2022)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

PSAT358 Graves’ Disease Complicated by Post-Operative Graves’ Ophthalmopathy and Pretibial Myxedema
por: Bowens, Brendan, et al.
Publicado: (2022)

ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022)

A case of Tocilizumab-induced thrombocytopenia in steroid-resistant Graves orbitopathy
por: Cuculescu, Victoria, et al.
Publicado: (2023)

SAT490 Graves’ Disease In Remission Aggravated By Himalayan Salt Consumption
por: Shakir, Mohamed K M, et al.
Publicado: (2023)

PSAT355 A Case Report Identifying Graves’ Ophthalmopathy in a Myasthenia Gravis Crisis and Response to Teprotumumab
por: Zia, Abdul, et al.
Publicado: (2022)

Treatment of Graves’ Disease With a Combination of Low Iodine Diet and Potassium Iodide Plus Radioactive Iodine Treatment
por: Ebrahim, Ismail, et al.
Publicado: (2021)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

SAT-606 Graves' Orbitopathy Treated with Kahaly's Protocol: IV High Dose Glucocorticoids
por: Patel, Bijal, et al.
Publicado: (2019)

ODP502 Nodular Pretibial Myxedema without Graves’ Orbitopathy: A Case Report
por: Veeramachaneni, Ravali, et al.
Publicado: (2022)

SAT-421 Novel Role of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
por: Guo, Yan, et al.
Publicado: (2020)

A Unique Presentation of Metastatic Follicular Thyroid Cancer Associated with Hyperthyroidism and an Active Graves’ Orbitopathy
por: Al-Jundi, Mohammad, et al.
Publicado: (2021)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab
por: Bowens, Brendan K., et al.
Publicado: (2022)

FRI554 Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab
por: Marta Niedzialkowska, Ewelina, et al.
Publicado: (2023)

SAT471 Hearing-Related Adverse Events in Teprotumumab Oncology Clinical Trials
por: Smith, Terry J, et al.
Publicado: (2023)

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

SUN-616 A Rapidly Enlarging Neck Mass in a 59-Year-Old Woman
por: Nath, Priti, et al.
Publicado: (2019)

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT-511 Alpha Gal Allergy in a Hypothyroid Patient
por: Slayden, Tanner A, et al.
Publicado: (2020)

SUN-569 Thyroid Associated Orbitopathy (TAO): An Unusual Presentation
por: Costa, Cláudia, et al.
Publicado: (2019)

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
por: Douglas, Raymond S, et al.
Publicado: (2022)

FRI568 Hashimoto’s Thyroiditis With Negative Antibodies In Association With Common Variable Immunodeficiency
por: Ebrahim, Ismail C, et al.
Publicado: (2023)

Improvement of Treatment Resistant Depression in a Patient With Primary Hypothyroidism and Thr92Ala5’ Type 2 Deiodinase Gene Polymorphism With Multiple Daily Doses of Triiodothyronine
por: Ahmed, Ziyan, et al.
Publicado: (2021)

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials
por: Kahaly, George J, et al.
Publicado: (2023)

SUN-595 Chronic Diarrhea as a Manifestation of Medullary Thyroid Cancer
por: Shakir, Mohamed, et al.
Publicado: (2019)

PSAT339 Long-term Follow Up of Three Cases of Periodic Paralysis
por: Bonsu, Osei, et al.
Publicado: (2022)

FRI565 Spontaneous Conversion Of Long-standing Hypothyroidism To Grave’s Disease: A Case Report
por: Rose Dominic, Maria, et al.
Publicado: (2023)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_54ekc2jk02aso8u9ltkcd3q218